News

The strategic collaboration aims to conduct a series of clinical programs to evaluate the response to mAb-based therapies, such as Erbitux (cetuximab), Rituxan (rituximab) and Herceptin (trastuzumab) and

When a patient has a serious spinal condition that requires the base of the skull (occiput) to be fused, or joined, to the neck (cervical-upper thoracic spine), this

Approximately 3300 women will be enrolled into two global studies to evaluate the contraceptive reliability of the patch starting in May 2009. The patch will be applied once

The joint venture program would include the implementation of six biotech manufacturing centers to be established in strategic locations in Africa. Based on preliminary information provided, each biotech

These products are available in 250mg capsules bottles of 100 and 500 and 500mg tablets bottles of 100 and 500. They are available for immediate shipment to wholesalers

The licensed technology, with pending patent applications, has been developed by Vincent Falanga, chairman of the department of dermatology and skin surgery at Roger Williams Medical Center, Providence,

Anti-platelet derived growth factor (anti-PDGF) therapy resulted in enhanced visual outcome and was associated with significant neovascular regression. Approximately 59% of patients treated with anti-PDGF and anti-vascular endothelial

At March 31, 2009, DURECT had cash and investments of $47.0 million, compared to cash and investments of $52.7 million at December 31, 2008; these figures include restricted

Total disposable revenues were $2.8 million versus $3.0 million in the third quarter of fiscal 2008. Disposable revenues associated with the company’s core AXP AutoXpress Platform (AXP) and